Please login to the form below

Not currently logged in
Email:
Password:

BMS' novel HIV drug clears phase II trial

Entry inhibitor BMS-660368 moves closer to first-in-class approval

Bristol-Myers Squibb (BMS)Bristol-Myers Squibb has reported positive trial results for BMS-660368, the first HIV drug to block the first stage of the virus's entry into host cells.

The phase IIb trial showed that BMS-663068 was as effective as a boosted protease inhibitor regimen - BMS' Reyataz (atazanavir sulfate) plus ritonavir - when given to treatment-experienced HIV-1 patients.

After 24 weeks of treatment with the new drug candidate, between 69 and 80 per cent of this pre-treated population had undetectable levels of HIV in the blood, compared to 75 per cent of the Reyataz group.

BMS-663068 is an orally-active prodrug that is converted in the body into another compound (BMS-625629) that blocks the attachment of HIV to CD4+ T cells as well as the entry of the virus.

HIV entry is a three stage process, consisting of attachment to the CD4 receptor, binding to a co-receptor such as CCR5 or CXCR4, and finally fusion with the T cell membrane to allow the viral particles to be injected into the cell interior.

Other HIV entry inhibitors are available, such as ViiV Healthcare's Selzentry/Celsentri (maraviroc) which blocks CCR5 binding and Roche's Fuzeon (enfuvirtide) which targets the final fusion stage, but BMS-660368 is the first to block the initial attachment of the virus.

While HIV is now considered an infection that can be managed with therapy, often allowing patients to survive for a near-normal lifespan, over time resistance to existing drug classes can develop, while tolerability issues can interfere with therapy.

The addition of a third class of entry inhibitor could provide an additional treatment option for these patients, according to BMS-663068 trial investigator Jacob Lalezari, who is assistant clinical professor of medicine at UCSF/Mount Zion Hospital in the US.

"The data suggest that BMS-663068 is potentially as effective as one of the current standards of care and may provide another method of suppressing the virus in treatment-experienced patients," he said.

Article by
Phil Taylor

6th March 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics